123 related articles for article (PubMed ID: 370532)
1. In vitro antitumor reactivity of mononuclear leukocytes from cancer patients receiving immunotherapy with BCG.
Mavligit GM; Hersh EM
Med Pediatr Oncol; 1978; 5(1):115-26. PubMed ID: 370532
[TBL] [Abstract][Full Text] [Related]
2. Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors.
Berkelhammer J; Mastrangelo MJ; Laucius JF; Bodurtha AJ; Prehn RT
Int J Cancer; 1975 Oct; 16(4):571-8. PubMed ID: 51835
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.
Berkelhammer J; Mastrangelo MJ; Bellet RE; Berd D; Prehn RT
Eur J Cancer (1965); 1979 Feb; 15(2):197-204. PubMed ID: 436896
[No Abstract] [Full Text] [Related]
4. Induction of melanoma specific monocyte cytotoxicity in patients receiving BCG immunotherapy.
Dufour FD; Morton DL
Surg Forum; 1977; 28():165-7. PubMed ID: 617405
[No Abstract] [Full Text] [Related]
5. Effect of immunotherapy with Corynebacterium parvum and methanol extraction residue of BCG administered intravenously on host defense function in cancer patients.
Hersh EM; Murphy SG; Quesada JR; Gutterman JU; Gschwind CR; Morgan J
J Natl Cancer Inst; 1981 Jun; 66(6):993-1002. PubMed ID: 6941048
[TBL] [Abstract][Full Text] [Related]
6. Immunologic tools to decipher efficacy of BCG immunotherapy in advanced breast cancer: a one year follow up study.
Saha K; Kapila H; Madan R; Shinghal RN
Asian Pac J Allergy Immunol; 1986 Dec; 4(2):139-48. PubMed ID: 3541948
[TBL] [Abstract][Full Text] [Related]
7. Effect of BCG on monocyte-mediated antibody-dependent cellular cytotoxicity in stage I melanoma.
Pehamberger H; Holubar K; Knapp W
Cancer; 1980 Sep; 46(5):1135-9. PubMed ID: 7214297
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of malignancy in humans. Current status.
Holmes EC; Eilber FR; Morton DL
JAMA; 1975 Jun; 232(10):1052-5. PubMed ID: 236402
[TBL] [Abstract][Full Text] [Related]
9. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
Nathanson L; Clark DA
Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
[No Abstract] [Full Text] [Related]
10. [Cancer and BCG].
Rumi LS
Acta Physiol Lat Am; 1981; 31(1):25-34. PubMed ID: 7187581
[TBL] [Abstract][Full Text] [Related]
11. Development of bacillus Calmette-Guérin-induced antitumor activity in peripheral blood mononuclear cells.
Koga S; Taniguchi K; Nishikido M; Kubota S; Yamashita S; Kanetake H; Saito Y
Urol Int; 1991; 47 Suppl 1():80-2. PubMed ID: 1949386
[TBL] [Abstract][Full Text] [Related]
12. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
[TBL] [Abstract][Full Text] [Related]
13. Increased monocyte-mediated cytostasis of lymphoid cell lines in breast and lung cancer patients.
Jerrells TR; Dean JH; Richardson G; Cannon GB; Herberman RB
Int J Cancer; 1979 Jun; 23(6):768-76. PubMed ID: 468410
[TBL] [Abstract][Full Text] [Related]
14. BCG as adjuvant immunotherapy for neoplasia.
Hersh EM; Gutterman JU; Mavligit GM
Annu Rev Med; 1977; 28():489-515. PubMed ID: 324372
[No Abstract] [Full Text] [Related]
15. The role of immunology in the diagnosis and treatment of cancer.
Humphrey LJ; Pierce GE
Prog Clin Cancer; 1975; 6():15-36. PubMed ID: 53858
[No Abstract] [Full Text] [Related]
16. Feasibility study of active immunotherapy in patients with solid tumors.
Gerner RE; Moore GE
Cancer; 1976 Jul; 38(1):131-43. PubMed ID: 779950
[TBL] [Abstract][Full Text] [Related]
17. Immunological monitoring in a controlled trial of immunotherapy in stage IIB malignant melanoma.
Embleton MJ; Ransom JH; McIllmurray MB; Reeves WG
Br J Cancer; 1978 Apr; 37(4):497-504. PubMed ID: 565645
[TBL] [Abstract][Full Text] [Related]
18. Immunological status may predict clinical outcome in BCG treated melanoma.
Reynolds PM; Grimsley G; Dawkins RL; Byrne MJ; Zilko PJ
Aust N Z J Med; 1980 Feb; 10(1):39-43. PubMed ID: 6966494
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy.
Richman SP; Gutterman JU; Hersh EM
Can Med Assoc J; 1979 Feb; 120(3):322-4, 329. PubMed ID: 371776
[TBL] [Abstract][Full Text] [Related]
20. The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
Green MD; MacKay IR; Buckley JC; Coates AS
Aust N Z J Surg; 1979 Jun; 49(3):335-9. PubMed ID: 289374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
